Related Experiment Video

Updated: May 13, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Use of transdermal estrogen in the management of advanced prostate cancer

Fay H Cafferty, Ruth E Langley, Paul D Abel

    Urologic Oncology
    |March 8, 2013
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
    08:38

    Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

    Published on: August 28, 2013

    Related Experiment Videos

    Last Updated: May 13, 2026

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
    07:25

    A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

    Published on: March 6, 2018

    Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
    08:38

    Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

    Published on: August 28, 2013

    Related Concept Videos

    Transdermal Drug Delivery Systems01:18

    Transdermal Drug Delivery Systems

    Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

    Articles linked to this work by shared authors, journal, and citation graph.

    Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial.

    PloS one·2026

    The role of DNA mismatch repair status in oesophagogastric cancer treated with perioperative chemotherapy: evidence from the MRC ST03 and OE05 trials.

    British journal of cancer·2026

    Decentralised Oncology Trials in the UK: Evidence, Regulation and Academic Clinical Trials Units' Perspectives.

    BMJ oncology·2026

    The clinical relevance of regional lymph node microarchitecture in oesophageal cancer patients - Results from the UK MRC OE02 trial.

    European journal of cancer (Oxford, England : 1990)·2026

    Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy.

    The Lancet. Oncology·2026

    The density of tumour infiltrating lymphocytes in oesophago-gastric cancer varies with disease stage, geographical region and treatment: a post hoc analysis of nine phase III clinical trials.

    Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026

    Impact of second-look TURBT on high grade recurrence and intravesical therapy in high-risk non-muscle-invasive bladder cancer: A 20-year experience.

    Urologic oncology·2026

    Nonmuscle-invasive bladder cancer after solid organ transplantation: Clinical outcomes and recurrence patterns.

    Urologic oncology·2026

    Comparing NCCN-based risk groups to the PROTEUS definition of high-risk localized prostate cancer to inform peri-operative care.

    Urologic oncology·2026

    Sociodemographic barriers to receiving adjuvant systemic therapy after nephrectomy for renal cell carcinoma.

    Urologic oncology·2026

    Real-world ctDNA test utilization and associated costs in US patients with bladder cancer who underwent radical cystectomy.

    Urologic oncology·2026

    Novel use of computed tomography-derived body composition to facilitate risk assessment in patients with bladder cancer.

    Urologic oncology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us